PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company pioneering a new generation of RNA therapeutics that utilise PYC’s proprietary library of naturally derived cell penetrating peptides to overcome the major challenges of current genetic medicines.
PYC believes its PPMO (Peptide conjugated Phosphorodiamidate Morpholino Oligomer) technology enables a safer and more effective RNA therapeutic to address the underlying drivers of a range of genetic diseases for which no treatment solutions exist today.
The Company is leveraging its leading-edge science to develop a pipeline of novel therapies including clinical stage and preclinical stage programs focused on inherited eye diseases and preclinical programs targeting a paediatric neurodevelopmental disease and a polycystic kidney disease.
PYC focuses on monogenic indications. These have the highest likelihood of approval from the start of clinical trials to market of any indication. Studies have shown monogenic diseases have 5x greater probability1 of achieving market entry compared to industry average.
PYC targets disease with no current treatment option for patients. This provides the potential for regulatory approval following two clinical trials (not three) resulting in a faster path to providing a life-changing treatment to patients
First-in-class drugs in rare diseases achieve rapid market penetration with a very short lead time to peak sales. PYC targets Orphan (rare) diseases with markets >$1bn1 per annum providing attractive shareholder returns.
MBBS (Hons) JD GDLP
Chief Executive Officer (Australia)
Rohan Hockings holds double degrees in medicine and law. He has worked across both disciplines following an internship at Sir Charles Gairdner Hospital and admission to practice in the Supreme Court of Victoria respectively.
He spent four years with McKinsey & Company and a further two years in the Private Equity industry before joining PYC Therapeutics. Rohan brings a deep affinity for conceptual thinking to PYC Therapeutics along with an understanding of the company’s technology and its commercialisation path.
Mr Tribe has a background in the accounting profession both in the UK and Australia. Moving into industry he became the Managing Director of a group of companies with interests in natural resources in Australia and overseas. The group also included a technology company which grew through both successful product development and acquisitions.
He was closely involved in establishing subsidiary operations in the USA, UK and Singapore to access markets worldwide.
Most recently he was the catalyst for the development for large retail operations in Western and South Australia.
Mr Tribe will contribute his broad experience in successfully commercialising technology internationally. He represents a large shareholding in PYC Therapeutics.
Non-Executive Director (USA)
Dr. Michael Rosenblatt is a currently a Senior Partner at Flagship Pioneering.
Dr. Rosenblatt joined Flagship from Merck, where he served as Executive Vice President and Chief Medical Officer from 2009 to 2016. During an earlier period at Merck, he led drug discovery efforts in ophthalmology, molecular biology, bone biology, virology, cancer research, gastroenterology, lipid metabolism and cardiovascular research.
He has held appointments as Dean of Tufts University School of Medicine; Robert H. Ebert Professor of Molecular Medicine and George R. Minot Professor of Medicine, both at Harvard Medical School; President, Harvard Faculty Dean and Senior Vice President for Academic Programs of Beth Israel Deaconess Medical Center; and Director of the Harvard-MIT Division of Health Sciences and Technology.
Dr. Rosenblatt has served as a founding scientist, scientific advisory board member or director of more than 12 biopharmaceutical companies. He received his BA summa cum laude from Columbia University and his MD magna cum laude from Harvard Medical School, and completed internship, residency and endocrinology training at the Massachusetts General Hospital.
Non-Executive Director (USA)
Jason Haddock has more than 20 years of financial and operational experience in the biopharmaceutical industry and currently serves as a Board Director of Codiak Biosciences, a biotech company developing precision exosome therapeutics. He served as CFO at Array BioPharma, Inc., where he was instrumental in the execution of an oncology-focused research, development and commercialization strategy that culminated in the successful launch of two new drugs and the company ultimately being acquired by Pfizer.
Prior, he worked at Bristol-Myers Squibb in a variety of finance, strategic, commercial and business development capacities, including CFO and COO roles for business units in Asia Pacific, Europe and the United States. Mr. Haddock has also served as CFO for ArcherDX as the company was acquired by Invitae to create a global leader in comprehensive cancer genetics and precision oncology. He holds a BS in accounting from Illinois State University and an EMBA from Washington University in St. Louis.
Subscribe to our mailing list:[email-subscribers-form id="2"]